Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro. Lilly claims ...

Lilly claims Premier Weight Loss is selling altered versions ... urgently call on regulators and law enforcement to do the same." RELATED: Eli Lilly launches higher doses of Zepbound, lowers price of ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro ... Lilly argues these claims are turning people toward compounded drugs and away from its FDA-approved treatments.

Eli Lilly alleges Willow falsely claims its products are safe ... which treats diabetes, and Zepbound, which treats obesity. Compound medicine providers were allowed to make and distribute ...

Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro. Related Experimental Eli Lilly weight ... is over The suits claim the companies are ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its ... Lilly also claims some of the sites are selling ...